



Description générale

Ifosfamide is a nitrogen mustard alkylating agent used in treatment protocols for bone and soft tissue sarcomas, and testicular and ovarian cancers.

INN	Ifosfamide
Codes ATC	L01AA06
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2009 (TRS 958) pour Other specified malignant neoplasms of the ovary Ajouté en 2009 (TRS 958) pour Ewing sarcoma of bone and articular cartilage of unspecified sites Ajouté en 2009 (TRS 958) pour Rhabdomyosarcoma primary site Ajouté en 2009 (TRS 958) pour Osteosarcoma of bone and articular cartilage of unspecified sites Ajouté en 2009 (TRS 958) pour Germ cell tumour of testis Ajouté en 2009 (TRS 958) pour Unspecified malignant neoplasms of ill-defined or unspecified sites Retiré en 2015 (TRS 994) pour Unspecified malignant neoplasms of ill-defined or unspecified sites Ajouté en 2021 (TRS 1035) pour Burkitt lymphoma including Burkitt leukaemia Ajouté en 2021 (TRS 1035) pour Malignant neoplasms of kidney, except renal pelvis Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-positive Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-negative
Wikipédia	Ifosfamide ↗
DrugBank	Ifosfamide ↗

Recommandations

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

